Cash Down, Shares Pledged: Nippon Sheet Glass Changes Hands

Partners Group Holdings Limited, the New Zealand holding company for Dai-ichi Life Group's insurer Partners Life, has agreed to pay NZ$630mn — about ¥59.6bn at the disclosed rate of NZ$1 to ¥94.65 — for all of Fidelity Life Assurance Company Limited, an Auckland insurer founded in 1973. The deal: The share purchase agreement was signed September 3, 2026, with sellers including Guardians of New Zealand Superannuation and Ngāi Tahu Investments. Completion is targeted for March to July 2027, subject to regulatory approval.

Why it matters: The purchase gives Dai-ichi's New Zealand operation full control of a second major life insurer in a market it already competes in through Partners Life.

Yamato Holdings is shutting the dedicated domestic air-cargo operation it built with Japan Airlines, ending the freighter contract by around June 2027. The board resolved the wind-down on September 3, roughly two years after launching the venture in 2024.

What changed: Yamato says the price gap between air and truck transport widened well beyond what it assumed at launch, as yen weakness and higher fuel costs pushed air-transport costs up faster than trucking.

Why it matters: Yamato built the freighter service into its answer to Japan's "2024 problem," the truck-driver capacity crunch created by new overtime caps. Abandoning it after two years says the economics of substituting planes for trucks did not hold up.

What to watch: The two companies signed a memorandum to complete the operating contract; CFO Yu Nomura is the disclosed contact as the wind-down proceeds.

China's National Medical Products Administration approved the self-injected, once-weekly formulation of Eisai and Biogen's Leqembi as initial therapy for early Alzheimer's disease, covering patients with mild cognitive impairment and mild dementia, effective September 2, 2026 local time.

What changed: Patients in China can now use a once-weekly at-home injection instead of the twice-monthly hospital infusions that have defined anti-amyloid treatment so far. China becomes the second market after the US to clear at-home dosing for the drug.

Why it matters: Removing the infusion-center requirement addresses a real adoption bottleneck for anti-amyloid therapies, whose logistics have limited uptake outside specialist clinics.

DyDo Group Holdings swung to a ¥2.8bn net profit for the six months to July, reversing a ¥1.36bn loss a year earlier, as operating profit jumped 388.2% to ¥6.74bn on sales up 2.0% to ¥120.1bn.

What changed: Overseas beverage sales rose 25.3%, lifting the group's results, even as DyDo kept pulling unprofitable vending machines off Japanese streets. The interim report also confirms DyDo's Turkish subsidiaries remain on IAS 29 hyperinflation accounting.

Why it matters: Growth abroad is doing more work than the shrinking domestic vending business, a mix shift worth watching as DyDo trims its home-market footprint.

A foreign investor's submission to Japan's Financial Services Agency, circulated ahead of the Disclosure Working Group's September 4 meeting, reviewed six Japanese issuers and found only six of 103 risk factors carried an actual number. Some filings reached shareholders just a week before the vote they were meant to inform. The critique: The submission argues the FSA's flagship fix — merging the business report into the annual securities report — addresses neither numberless risk disclosure nor late delivery.

Why it matters: Disclosure timing and specificity affect every investor trying to vote informed at any Japanese annual meeting, not just the six issuers reviewed.

Japan's Fair Trade Commission recommended that Nichirin, a Kobe hose maker with ¥2.158bn in capital, pay any outstanding balance owed to 25 smaller suppliers after finding it left them storing 1,048 molds and jigs for up to 22 months without ordering the parts those tools were meant to produce.

What changed: Nichirin had already paid ¥9.79mn of the storage costs by July 31; the JFTC's order covers whatever remains once the commission confirms the calculation.

Why it matters: Free tooling storage without matching orders is a recurring subcontracting complaint in Japan's manufacturing supply chain, and this recommendation gives smaller suppliers a concrete enforcement precedent.

Five amended securities reports filed on the same day show the medical-equipment distributor's disclosed lease commitments were too low every year from mid-2020 to mid-2025, in one year by more than a billion yen.

Axium Capital, a 17% holder of NIPPO, is pressing the industrial-gas distributor to borrow for a buyback worth up to ¥10bn at ¥4,000 a share and to lift its payout ratio to 100% or more. The threat: Axium says it may move to dismiss directors if the board declines.

Why it matters: A debt-funded buyback demand paired with a board-ouster threat is activist pressure with teeth, and NIPPO's board now has to decide whether to fight or fund it.